Here are five things to know.
- Symjepi is a single-dose prefilled syringe of epinephrine intended to treat emergency allergic reactions, including anaphylaxis.
- The injection will directly compete with Mylan’s EpiPen, which holds a majority of the epinihprine injection market.
- Adamis has not disclosed an official price for Symjepi. The drugmaker hopes to sell a two-pack of Symjepi for cheaper than Mylan’s generic EpiPens, which cost $300 for a pack of two, reports CBS News.
- The drugmaker plans to launch the product in the second half of 2017.
- Adamis will also submit a new drug application to the FDA for a lower-dose version of Symjepi, which will compete with Mylan’s EpiPen Jr.
More articles on supply chain:
Nevada governor signs drug price transparency legislation: 5 things to know
Hospira recalls several injectables over sterility concerns
Trump administration readies executive order addressing drug prices
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
